Tudor Investment Corp ET AL Purchases Shares of 37,595 IDEAYA Biosciences, Inc. $IDYA

Tudor Investment Corp ET AL acquired a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 37,595 shares of the company’s stock, valued at approximately $1,023,000.

Other large investors have also recently made changes to their positions in the company. Aster Capital Management DIFC Ltd acquired a new position in shares of IDEAYA Biosciences during the third quarter valued at about $38,000. Abich Financial Wealth Management LLC acquired a new stake in shares of IDEAYA Biosciences in the 3rd quarter worth about $58,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of IDEAYA Biosciences in the 2nd quarter worth about $61,000. Daiwa Securities Group Inc. lifted its position in IDEAYA Biosciences by 16.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after acquiring an additional 436 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in IDEAYA Biosciences by 39.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 3,344 shares of the company’s stock valued at $70,000 after acquiring an additional 940 shares in the last quarter. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Stock Performance

IDEAYA Biosciences stock opened at $31.45 on Tuesday. IDEAYA Biosciences, Inc. has a fifty-two week low of $13.45 and a fifty-two week high of $39.28. The firm’s 50-day simple moving average is $32.91 and its 200 day simple moving average is $32.11. The stock has a market cap of $2.76 billion, a PE ratio of -24.01 and a beta of 0.09.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, February 17th. The company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.09. The firm had revenue of $21.75 million during the quarter, compared to analysts’ expectations of $5.95 million. During the same quarter last year, the business posted ($1.49) EPS. The company’s quarterly revenue was up 55.7% on a year-over-year basis. As a group, analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Insider Activity

In other IDEAYA Biosciences news, Director Jeffrey Stein purchased 50,000 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was bought at an average cost of $32.96 per share, with a total value of $1,648,000.00. Following the completion of the transaction, the director owned 54,281 shares of the company’s stock, valued at $1,789,101.76. The trade was a 1,167.95% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 2.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on IDYA shares. Royal Bank Of Canada reiterated an “outperform” rating and set a $49.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, February 18th. Wall Street Zen lowered IDEAYA Biosciences from a “buy” rating to a “sell” rating in a report on Saturday, February 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a research report on Wednesday, February 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Thursday, January 22nd. Finally, Citigroup increased their price target on IDEAYA Biosciences from $64.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Fifteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, IDEAYA Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $48.69.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.